* Co-Diagnostics Inc CODX.OQ CODX.O is expected to show
a fall
in quarterly revenue when it reports results on November 10.
* The Salt Lake City Utah-based company is expected to
report a
73.5% decrease in revenue to $7.977 million from $30.1 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Co-Diagnostics Inc
is for
a loss of 4 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for
Co-Diagnostics
Inc is $9, above its last closing price of $3.55.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 0.15 0.10 -0.08 Missed -182.8
Mar. 31 2022 0.17 0.17 0.34 Beat 96.2
Dec. 31 2021 0.12 0.12 0.25 Beat 108.3
Sep. 30 2021 0.20 0.21 0.38 Beat 83.9
Jun. 0.22 0.22 0.33 Beat 50
30 2021
Mar. 31 2021 0.22 0.22 0.26 Beat 18.2
Dec. 31 2020 0.48 0.48 0.45 Missed -5.6
Sep. 30 2020 0.61 0.63 0.53 Missed -16.3
This summary was machine generated November 9 at 02:14 GMT. All
figures in US dollars unless otherwise stated